FY2025 Earnings Estimate for TSE:MDP Issued By Stifel Canada

Medexus Pharmaceuticals Inc. (TSE:MDP) – Analysts at Stifel Canada lifted their FY2025 earnings per share (EPS) estimates for shares of Medexus Pharmaceuticals in a research report issued to clients and investors on Monday, January 13th. Stifel Canada analyst J. Keywood now anticipates that the company will post earnings of $0.03 per share for the year, up from their prior forecast of ($0.03). The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Other equities analysts also recently issued reports about the company. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Stifel Nicolaus increased their price objective on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price for the company in a report on Wednesday, January 8th. Finally, Leede Financial set a C$8.25 price target on shares of Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a report on Monday, September 30th. Two research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, Medexus Pharmaceuticals has an average rating of “Strong Buy” and an average price target of C$5.58.

Medexus Pharmaceuticals Trading Down 3.1 %

Shares of TSE:MDP opened at C$4.33 on Thursday. The stock has a fifty day simple moving average of C$2.92 and a two-hundred day simple moving average of C$2.60. Medexus Pharmaceuticals has a 12-month low of C$1.47 and a 12-month high of C$4.60. The stock has a market capitalization of C$106.21 million, a price-to-earnings ratio of 86.60 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.